Newcastle University, Newcastle upon Tyne, United Kingdom.
J Clin Oncol. 2010 Nov 10;28(32):4790-9. doi: 10.1200/JCO.2010.28.3473. Epub 2010 May 3.
Numerous studies have documented that adolescents and young adults (AYAs) experience a significant cancer burden as well as significant cancer mortality compared with other age groups. The reasons for the disparate outcomes of AYAs and other age groups are not completely understood and are likely to be multifactorial, including a range of sociodemographic issues unique to these individuals as well as differences between adolescents, younger pediatric patients, and adults in the pharmacology of anticancer agents. Because adolescence is a period of transition from childhood to early adulthood, numerous physical, physiologic, cognitive, and behavioral changes occur during this time. In this review, we provide an overview of the unique developmental physiology of the adolescent and explain how these factors and the behavioral characteristics of adolescents may affect the pharmacology of anticancer agents in this patient population. Finally, we describe examples of studies that have assessed the relation between drug disposition and age, focusing on the AYA age group.
大量研究表明，与其他年龄组相比，青少年和年轻成年人（AYAs）的癌症负担和癌症死亡率都很高。AYAs 和其他年龄组的结果存在差异的原因尚不完全清楚，可能是多因素的，包括这些人特有的一系列社会人口问题，以及青少年、年轻儿科患者和成年人在抗癌药物药理学方面的差异。由于青春期是从儿童期向成年早期过渡的时期，在此期间会发生许多身体、生理、认知和行为上的变化。在这篇综述中，我们提供了青少年独特的发育生理学概述，并解释了这些因素和青少年的行为特征如何影响该患者群体中抗癌药物的药理学。最后，我们描述了评估药物处置与年龄之间关系的研究示例，重点关注 AYA 年龄组。
